Cite
HARVARD Citation
Kandalaft, L. et al. (n.d.). 182P Cancer vaccines based on whole-tumor-lysate or neoepitopes with validated HLA-binding outperform those with predicted HLA-binding affinity. Immuno-oncology technology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kandalaft, L. et al. (n.d.). 182P Cancer vaccines based on whole-tumor-lysate or neoepitopes with validated HLA-binding outperform those with predicted HLA-binding affinity. Immuno-oncology technology. p. . [Online].